RIPK1 and COVID-19: Xu et al. confirmed that RIPK1, which is increased in COVID-19 patients who experience cytokine storm, was also activated in SARS-CoV-2 infection organoids and inhibited viral entry after treatment with RIPK-1 inhibitors [50].